OncoCyte Corporation (OCX) financial statements (2021 and earlier)

Company profile

Business Address 15 CUSHING
IRVINE, CA 92618
State of Incorp. CA
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments228812
Cash and cash equivalents228810
Short-term investments0012
Prepaid expense0  0
Other current assets0  0
Other undisclosed current assets000 
Total current assets:239913
Noncurrent Assets
Property, plant and equipment4111
Long-term investments and receivables11   
Long-term investments11   
Intangible assets, net (including goodwill)  11
Intangible assets, net (excluding goodwill)  11
Prepaid expense0   
Deposits noncurrent assets  00
Other noncurrent assets0   
Other undisclosed noncurrent assets20  
Total noncurrent assets:17122
TOTAL ASSETS:40101014
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2111
Accounts payable000 
Accrued liabilities  11
Employee-related liabilities11  
Other undisclosed accounts payable and accrued liabilities  00
Debt1110
Due to related parties0223
Other undisclosed current liabilities1101
Total current liabilities:4644
Noncurrent Liabilities
Long-term debt and lease obligation2110
Long-term debt, excluding current maturities201 
Finance lease, liability0
Capital lease obligations000
Other undisclosed noncurrent liabilities3   
Total noncurrent liabilities:5110
Total liabilities:9665
Stockholders' equity
Stockholders' equity attributable to parent313410
Common stock125756046
Accumulated other comprehensive loss  (1)(1)
Accumulated deficit(94)(71)(55)(35)
Total stockholders' equity:313410
TOTAL LIABILITIES AND EQUITY:40101014

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit: 0  
Operating expenses(22)(15)(19)(11)
Other undisclosed operating loss (0)  
Operating loss:(22)(15)(19)(11)
Nonoperating expense(0)(1)(1)(0)
Other nonoperating income (expense)(0)0  
Interest and debt expense(0)(0)  
Net loss:(22)(16)(19)(11)
Other undisclosed net income attributable to parent00  
Net loss available to common stockholders, diluted:(22)(16)(19)(11)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(22)(16)(19)(11)
Comprehensive loss:(22)(16)(19)(11)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)(0)
Comprehensive loss, net of tax, attributable to parent:(22)(16)(20)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: